Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      ILD, Cardiotoxicities Move to the Forefront of Treatment-Related AE Management in Breast Cancer

      March 13, 2023
      By Lindsay Fischer
      Article

      Patricia Jakel, RN, MN, AOCN discusses adverse event management in the age of new breast cancer treatments.

      Patricia Jakel, RN, MN, AOCN

      Patricia Jakel, RN, MN, AOCN

      With new therapies shifting the treatment landscape for patients with breast cancer, management of interstitial lung disease (ILD) and cardiac toxicities have moved to the forefront of nursing considerations, according to Patricia Jakel, RN, MN, AOCN.1

      “Many anticancer agents and radiation have the potential to cause cardiac issues in [patients with] cancer,” Jakel, who is an advance practice nurse and associate professor at the UCLA school of nursing, and a breast cancer survivor, said during a presentation at the 40th Annual Miami Breast Cancer Conference®. Moreover, “ILD is a potentially lethal [adverse] effect [AE] in breast cancer treatment and patients should be closely monitored by a health care professional.”

      Jakel presented on managing treatment-related toxicities in breast cancer as part of the conference’s nursing track. In her talk, she highlighted the need to manage ILD and cardiac complications, as well fatigue, nausea, and issues that may affect sexual health. She shared that nurses can have a huge impact in helping patients get through their treatment.1

      “We are the total psychosocial support for many of our patients,” she said. “The key source of information. We're the interpreters, the educators, the people that keep the patients grounded.”

      Interstitial Lung Disease (ILD)

      ILD is characterized by inflammation and fibrosis of the lung interstitial. Drug-induced ILD encompasses a group of serious—and sometimes fatal—pulmonary conditions. The rates of ILD can range from 2% to 20% for patients with breast cancer depending on the agents and treatment combinations they are receiving.2

      “Treatment-induced ILD happens, but it’s not 1 diagnosis,” Jakel said. “You can’t look at a patient and say, ‘Oh, yeah, that’s what they have.’ It’s an umbrella term for over 200 diverse lung conditions.”

      Some treatments associated with ILD include common agents used for patients with HER2-positive metastatic breast cancer, such as trastuzumab (Herceptin), lapatinib (Tykerb), ado-trastuzumab emtansine (Kadcyla; T-DM1), and fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd), trastuzumab duocarmazine. Additionally, checkpoint inhibitors, CDK4/6 inhibitors, mTOR inhibitors, and radiation therapy have associations with this AE. Of note, the highest ILD incidence was reported in patients who received trastuzumab combined with an mTOR inhibitor (everolimus [Afinitor; range, 7.3%-21.4%] or sirolimus [Rapamune; 9.1%]), and in patients who received T-DXd (range, 13.6%-17.4%). However, in terms of ILD-related deaths, the highest incidence was among patients receiving T-DXd (range, 1.7%-2.2%), whereas in patients receiving trastuzumab, lapatinib, T-DM1, or trastuzumab duocarmazine, the incidence was lower (range, 0.1%-0.6%).2,3

      For patient education, the most common symptoms are a dry, hacking cough that does not produce phlegm, extreme fatigue and weakness, shortness of breath or labored breathing, a lack of appetite, unexplained weight loss, mild chest pain, and bleeding in the lungs.1

      “[Patients] should definitely be calling you if they are coughing up blood,” Jakel said.

      Unfortunately, treatment guidelines are lacking for managing drug-induced ILD, Jakel said. Currently, detailed treatment management outlines are only available for T-DXd and trastuzumab combined with paclitaxel and everolimus, although a multidisciplinary team in Italy developed a step-by-step diagnosis and therapeutic guideline for patients who developed drug-induced ILD.4

      Cardiac Complications

      As earlier detection and new treatment options have improved the quality of cancer care, the number of cancer survivors has dramatically increased. However, many survivors are at a higher risk for cardiovascular disease (CVD) than recurrent cancer, and symptoms of CVD may not manifest for several years after treatment.1 Cardio-oncology has been considered a relevant aspect of cancer care since the early 2000s when patients with breast cancer who had undergone HER2-targeted therapies experienced elevated rates of heart failure.5

      Treatments such as anthracyclines, intravenous (IV) HER2-targeted therapies, and VEGF pathway inhibitors are all associated with an increased risk of left ventricular dysfunction (LVD) and can be managed with angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and angiotensin receptor blockers (ARB).

      These breast cancer treatments as well as are also all linked with heart failure and can be managed with ACE inhibitors, ARBs, and beta blockers. Moreover, QTc prolongation can be brought on by HDAC inhibitors, CDK4/6 inhibitors VEGF pathway inhibitors, antiemetics, and can be managed through correcting electrolyte imbalances and periodic EKGS.

      Moreover, Jakel outlined some breast cancer treatments with risk factors for certain cardiac toxicities: both antimicrotubular agents, taxanes and vinca alkaloids can cause myocardial ischemia, LVD, health failure, hypertension and thromboembolism whereas immune checkpoint inhibitors have been linked to myocarditis (1%-4%), heart failure, pericarditis, and arrythmias.6 Radiation therapy is associated with cardiomyopathy, heart failure, arrythmias, sick sinus, value regurgitation, and pericarditis.7

      Therefore, patients with cancer should be assessed for a history of previous cardiovascular disease, age, hypertension, diabetes, hyperlipidemia, chronic renal disease, as well as their current lifestyle risk factors, such as their smoking status or whether they have a body mass index over 30. Patients should also be queried on their previous cardiotoxic treatments, such as anthracycline, radiation (especially to the left chest or mediastinum), or trastuzumab.8

      “By 2026, the number of cancer survivors will exceed 20 million,” Jakel noted, in emphasizing the importance of proactively managing heart disease. “We don’t want 20 million [individuals] with heart disease because heart disease is still the No. 1 killer.”

      Nausea and Vomiting

      Nausea and vomiting continue to rank high as an AE for anticancer treatment and therefore require nursing intervention and education, Jakel noted. She acknowledged that the management of this AE can be overwhelming at times, but that in her experience, a 4-drug regimen with NK 1 RA, 5-HT 3 RA, dexamethasone, and olanzapine was effective.9

      “The [National Comprehensive Cancer Network] NCCN guidelines will make your head swivel, but olanzapine can be a life changer for high-dose chemotherapy patients,” she said. “The steroids are a wonder and then adding a little bit of olanzapine at night was very helpful.”

      She also highlighted that grape juice was found to be effective against chemotherapy-induced nausea and vomiting (CINV) and is recommended in the Oncology Nursing Society guidelines.10

      “Grape juice was effective in decreasing CINV,” she said, “And it was common grape juice; it wasn’t ‘Gucci grape juice.’”

      Sexual Health

      Jakel concluded her talk by noting that sexual health is often impacted by treatment and that routine discussions with patients on sexual health are by and large, not happening enough. She shared an anecdote of an adult patient who asked her if she was able to have sex with her husband. When Jakel asked her why no one had ever discussed that with her before, she said that her father was the one who took her to appointments, and she didn’t want to ask in front of him. She was taking advantage of a short minute as he was bringing the car around to ask Jakel this question.

      Jakel pointed out that pediatricians often ask parents to step out of the room before asking teenagers personal questions, and that perhaps in cancer care, the same practice is needed.

      References

      1. Jakel P. Managing treatment-related toxicities in breast cancer. Presented at: 40th Annual Miami Breast Cancer Conference; March 2-5, 2023; Miami Beach, FL.
      2. Law JW, Campbell A, Weller C, et al. Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis. Breast Cancer Res Treat. 2022;196(3):603-611. doi:10.1007/s10549-022-06738-6
      3. Hackshaw MD, Danysh HE, Singh J, et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183(1):23-39. doi:10.1007/s10549-020-05754-8
      4. Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404. doi:10.1016/j.esmoop.2022.100404
      5. Pituskin E, Kirkham AA, Cox-Kennett N, et al. Rehabilitation needs in cancer treatment-related cardiotoxicity. Semin Oncol Nurs. 2020;36(1):150986. doi:10.1016/j.soncn.2020.150986
      6. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263-302. doi:10.2165/00002018-200022040-00002.
      7. Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309-325. doi:10.3322/caac.21341
      8. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400.
      9. NCCN. Clinical practice guidelines in oncology. Antiemesis, version 1.2023. Accessed February 24, 2023. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
      10. Ingersoll GL, Wasilewski A, Haller M,et al. Effect of concord grape juice on chemotherapy-induced nausea and vomiting: results of a pilot study. Oncol Nurs Forum. 2010;37(2):213-21. doi:10.1188/10.ONF.213-221

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a woman with shoulder-length black hair wearing headphones and a white sweater
      Photo of a woman with brown hair and bangs, surrounded by a blue border
      Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
      Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
      Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
      Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
      Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
      Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
      Related Content

      Graphic of a breast with a tumor

      T-DXd Regimen Improves pCR in Early HER2+ Breast Cancer

      Sabrina Serani
      May 13th 2025
      Article

      T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Photo of acupuncture needles resting in a bowl

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Ariana Pelosci
      April 22nd 2025
      Article

      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast on a blue background

      Tailored Intervention Aids Distress, Recovery After Breast-Conserving Surgery

      Kristie L. Kahl
      April 14th 2025
      Article

      Assessment of psychological needs and offering tailored interventions immediately after BCS helps patients with breast cancer in the outpatient setting.


      Close-up photo of a patient's hand being held by a the hands of a health care professional

      Social Health Determinants Impact Psychoneurological Symptoms in BC Survivors

      Kyle Doherty
      April 11th 2025
      Article

      Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

      Related Content

      Graphic of a breast with a tumor

      T-DXd Regimen Improves pCR in Early HER2+ Breast Cancer

      Sabrina Serani
      May 13th 2025
      Article

      T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Photo of acupuncture needles resting in a bowl

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Ariana Pelosci
      April 22nd 2025
      Article

      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast on a blue background

      Tailored Intervention Aids Distress, Recovery After Breast-Conserving Surgery

      Kristie L. Kahl
      April 14th 2025
      Article

      Assessment of psychological needs and offering tailored interventions immediately after BCS helps patients with breast cancer in the outpatient setting.


      Close-up photo of a patient's hand being held by a the hands of a health care professional

      Social Health Determinants Impact Psychoneurological Symptoms in BC Survivors

      Kyle Doherty
      April 11th 2025
      Article

      Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

      Latest Conference Coverage

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.